Silvennoinen-Kassinen S, Karttunen R, Tiilikainen A, Huttunen K
Nephron. 1987;46(3):243-6. doi: 10.1159/000184362.
We studied the effect of an immuno-stimulating agent, isoprinosine, which is being marketed as an antiviral drug, on some immune functions in vitro in 14 uremic patients treated by hemodialysis and in 10 healthy controls. PHA and PPD induced stimulations of DNA synthesis and interleukin-2 (Il-2) production and NK cell activity were measured from peripheral blood mononuclear cells cultured with and without isoprinosine. PHA responses were enhanced by isoprinosine (100 micrograms/ml) both in the patient group (p less than 0.001) and in the control group (p less than 0.05) but PPD responses in neither. The enhancement of PHA responses was not due to an increased production of Il-2(T-cell growth factor). Isoprinosine augmented NK activity in those patients whose NK activity was initially low. No enhancement could be seen in the controls or in those patients whose NK activity was comparable to that of the controls. Our results motivate a clinical study with isoprinosine in uremic patients at the risk of virus infection.
我们研究了一种免疫刺激剂异丙肌苷（现作为抗病毒药物销售）对14例接受血液透析治疗的尿毒症患者及10名健康对照者某些体外免疫功能的影响。通过在添加和不添加异丙肌苷的情况下培养外周血单个核细胞，测定了PHA和PPD诱导的DNA合成刺激、白细胞介素-2（Il-2）产生及NK细胞活性。在患者组（p<0.001）和对照组（p<0.05）中，异丙肌苷（100微克/毫升）均增强了PHA反应，但对PPD反应均无增强作用。PHA反应的增强并非由于Il-2（T细胞生长因子）产生增加。异丙肌苷增强了那些NK活性最初较低的患者的NK活性。在对照组或NK活性与对照组相当的患者中未观察到增强作用。我们的结果促使开展一项针对有病毒感染风险的尿毒症患者使用异丙肌苷的临床研究。
